{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:58:06Z","timestamp":1772895486767,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Malignant pleural mesothelioma (MPM) is a rare, aggressive malignancy of the pleural cavity linked to asbestos exposure. The combination of pemetrexed and platinum is a standard first-line therapy for malignant pleural mesothelioma. Despite some progress, almost all MPM patients experience progression after first-line therapy.\u00a0The second-line treatment is still being under discussion and there are very limited data available on the second-line and subsequent treatments.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The retrospective analysis included 57 patients (16 females and 41 males) from two Polish oncological institutions treated for advanced mesothelioma between 2013 and 2019. We analysed the efficacy of first-line and second-line therapy: progression-free survival (PFS), overall survival (OS), overall response rate (ORR).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the first-line treatment, 55 patients received pemetrexed-based chemotherapy (PBC) and two cisplatin in monotherapy. Patients\u2019 characteristics at baseline: median age was 64.2\u00a0years, ECOG PS\u2009\u2264\u20091 (86.2%), epithelial histology (85.7%). Median PFS and OS were 7.6\u00a0months and 14\u00a0months, respectively. Patients with ECOG PS\u2009\u2264\u20091 vs\u2009&gt;\u20091 had a longer median OS (14.8\u00a0months vs 9.7\u00a0months, <jats:italic>p<\/jats:italic>\u2009=\u20090.057). One-year OS and PFS were 60.9% and 32.0%, respectively. Disease control rate (DCR) was 82.5%. Response to first-line therapy: PFS\u2009\u2265\u20096\u00a0months and PFS\u2009\u2265\u200912\u00a0months had a significant impact on median OS. Twelve patients received second-line therapy (seven PBC and five other cytotoxic single agents: navelbine, gemcitabine, or adriamycin\/vincristine\/methotrexate triplet).\u00a0Median PFS and OS were 3.7\u00a0months and 7.2\u00a0months, respectively. DCR was 83%. One-year OS and PFS were 37% and 16.7%, respectively.<\/jats:p>\n                <jats:p>In the group receiving PBC, OS was prolonged by 4.5\u00a0months compared to the non-PBC group (6.0\u00a0months vs 10.5\u00a0months, <jats:italic>p<\/jats:italic>\u2009=\u20090.47).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Patients who benefited from first-line therapy and had prolonged PFS at first-line and achieve PFS longer than 6\u00a0months at first-line should be offered second-line treatment. Consideration of retreatment with the same cytotoxic agent could to be a viable option when no other treatment are available.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-09490-8","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T15:03:33Z","timestamp":1650467013000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Systemic treatment in patients with malignant pleural mesothelioma \u2013 real life experience"],"prefix":"10.1186","volume":"22","author":[{"given":"Barbara","family":"Zi\u00f3\u0142kowska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo\u017cena","family":"Cybulska-Stopa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Papantoniou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafa\u0142","family":"Suwi\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"issue":"9","key":"9490_CR1","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1038\/bjc.2014.478","volume":"111","author":"A Linton","year":"2014","unstructured":"Linton A, Pavlakis N, O\u2019Connell R, Soeberg M, Kao S, Clarke S, Vardy J, van Zandwijk N. Factors Associated with Survival in a Large Series of Patients with Malignant Pleural Mesothelioma in New South Wales. Br J Cancer. 2014;111(9):1860\u20139. https:\/\/doi.org\/10.1038\/bjc.2014.478.","journal-title":"Br J Cancer"},{"issue":"1","key":"9490_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/ajim.22261","volume":"57","author":"KM Bang","year":"2014","unstructured":"Bang KM, Mazurek JM, Wood JM, Hendricks SA. Diseases Attributable to Asbestos Exposure: Years of Potential Life Lost, United States, 1999\u20132010. Am J Ind Med. 2014;57(1):38\u201348. https:\/\/doi.org\/10.1002\/ajim.22261.","journal-title":"Am J Ind Med"},{"issue":"10","key":"9490_CR3","doi-asserted-by":"publisher","first-page":"716","DOI":"10.2471\/BLT.11.086678","volume":"89","author":"V Delgermaa","year":"2011","unstructured":"Delgermaa V, Takahashi K, Park E-K, Le GV, Hara T, Sorahan T. Global Mesothelioma Deaths Reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 2011;89(10):716\u201324. https:\/\/doi.org\/10.2471\/BLT.11.086678 (724A-724C).","journal-title":"Bull. World Health Organ"},{"issue":"6","key":"9490_CR4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"9490_CR5","first-page":"718","volume":"34","author":"BP Lanphear","year":"1992","unstructured":"Lanphear BP, Buncher CR. Latent Period for Malignant Mesothelioma of Occupational Origin. J Occup Med. 1992;34(7):718\u201321.","journal-title":"J Occup Med"},{"issue":"2","key":"9490_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/JTO.0b013e31827740f0","volume":"8","author":"DR Gomez","year":"2013","unstructured":"Gomez DR, Hong DS, Allen PK, Welsh JS, Mehran RJ, Tsao AS, Liao Z, Bilton SD, Komaki R, Rice DC. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol. 2013;8(2):238\u201345. https:\/\/doi.org\/10.1097\/JTO.0b013e31827740f0.","journal-title":"J Thorac Oncol"},{"issue":"23","key":"9490_CR7","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1200\/JCO.2016.67.2675","volume":"34","author":"A Rimner","year":"2016","unstructured":"Rimner A, Zauderer MG, Gomez DR, Adusumilli PS, Parhar PK, Wu AJ, Woo KM, Shen R, Ginsberg MS, Yorke ED, Rice DC, Tsao AS, Rosenzweig KE, Rusch VW, Krug LM. Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma. J Clin Oncol. 2016;34(23):2761\u201327618. https:\/\/doi.org\/10.1200\/JCO.2016.67.2675.","journal-title":"J Clin Oncol."},{"issue":"14","key":"9490_CR8","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III Study of Pemetrexed in Combination with Cisplatin versus Cisplatin Alone in Patients with Malignant Pleural Mesothelioma. J Clin Oncol. 2003;21(14):2636\u201344. https:\/\/doi.org\/10.1200\/JCO.2003.11.136.","journal-title":"J Clin Oncol"},{"issue":"7","key":"9490_CR9","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","volume":"3","author":"A Santoro","year":"2008","unstructured":"Santoro A, O\u2019Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C. Pemetrexed plus Cisplatin or Pemetrexed plus Carboplatin for Chemona\u00efve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program. J Thorac Oncol. 2008;3(7):756\u201363. https:\/\/doi.org\/10.1097\/JTO.0b013e31817c73d6.","journal-title":"J Thorac Oncol"},{"issue":"10026","key":"9490_CR10","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivi\u00e8re F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy M-P, Morin F, Creveuil C, Parienti J-J, Scherpereel A, French Cooperative Thoracic Intergroup (IFCT). Bevacizumab for Newly Diagnosed Pleural Mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A Randomised, Controlled, Open-Label, Phase 3 Trial. Lancet. 2016;387(10026):1405\u201314. https:\/\/doi.org\/10.1016\/S0140-6736(15)01238-6.","journal-title":"Lancet"},{"issue":"10","key":"9490_CR11","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/j.jtho.2020.08.004","volume":"15","author":"P Baas","year":"2020","unstructured":"Baas P, Scherpereel A, Nowak A, Fujimoto N, Peters S, Tsao A, Mansfield A, Popat S, Jahan T, Antonia S, Oulkhouir Y. ID: 2908 first-line nivolumab+ ipilimumab vs chemotherapy in unresectable malignant pleural mesothelioma: CheckMate 743. JThoracic Oncol. 2020;15(10):e42.","journal-title":"JThoracic Oncol"},{"issue":"11","key":"9490_CR12","doi-asserted-by":"publisher","first-page":"502","DOI":"10.46883\/ONC.2020.3411.0502","volume":"34","author":"K Wright","year":"2020","unstructured":"Wright K. FDA Approves Nivolumab Plus Ipilimumab for Previously Untreated Unresectable Malignant Pleural Mesothelioma. Oncol. 2020;34(11):502\u20133. https:\/\/doi.org\/10.46883\/ONC.2020.3411.0502.","journal-title":"Oncol"},{"issue":"10","key":"9490_CR13","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1200\/JCO.2006.09.9887","volume":"26","author":"J Jassem","year":"2008","unstructured":"Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C. Phase III Trial of Pemetrexed plus Best Supportive Care Compared with Best Supportive Care in Previously Treated Patients with Advanced Malignant Pleural Mesothelioma. J Clin Oncol. 2008;26(10):1698\u2013704. https:\/\/doi.org\/10.1200\/JCO.2006.09.9887.","journal-title":"J Clin Oncol"},{"key":"9490_CR14","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1186\/1756-0500-5-482","volume":"5","author":"A Bearz","year":"2012","unstructured":"Bearz A, Talamini R, Rossoni G, Santo A, de Pangher V, Fasola G, Rosetti F, Favaretto A, Gregorc V, Berretta M, Santarossa S, Berto E, Tirelli U. Re-Challenge with Pemetrexed in Advanced Mesothelioma: A Multi-Institutional Experience. BMC Res Notes. 2012;5:482. https:\/\/doi.org\/10.1186\/1756-0500-5-482.","journal-title":"BMC Res Notes"},{"issue":"1","key":"9490_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.lungcan.2010.12.004","volume":"72","author":"GL Ceresoli","year":"2011","unstructured":"Ceresoli GL, Zucali PA, De Vincenzo F, Gianoncelli L, Simonelli M, Lorenzi E, Ripa C, Giordano L, Santoro A. Retreatment with Pemetrexed-Based Chemotherapy in Patients with Malignant Pleural Mesothelioma. Lung Cancer. 2011;72(1):73\u20137. https:\/\/doi.org\/10.1016\/j.lungcan.2010.12.004.","journal-title":"Lung Cancer"},{"issue":"3","key":"9490_CR16","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.lungcan.2011.08.011","volume":"75","author":"PA Zucali","year":"2012","unstructured":"Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collov\u00e0 E, Follador A, Lo Dico M, Moretti A, De Vincenzo F, Lorenzi E, Perrino M, Giordano L, Farina G, Santoro A, Garassino M. Second-Line Chemotherapy in Malignant Pleural Mesothelioma: Results of a Retrospective Multicenter Survey. Lung Cancer. 2012;75(3):360\u20137. https:\/\/doi.org\/10.1016\/j.lungcan.2011.08.011.","journal-title":"Lung Cancer"},{"issue":"Suppl 2","key":"9490_CR17","doi-asserted-by":"publisher","first-page":"S333","DOI":"10.21037\/jtd.2017.10.159","volume":"10","author":"I Petrini","year":"2018","unstructured":"Petrini I, Lucchesi M, Puppo G, Chella A. Medical Treatment of Malignant Pleural Mesothelioma Relapses. J Thorac Dis. 2018;10(Suppl 2):S333\u201341. https:\/\/doi.org\/10.21037\/jtd.2017.10.159.","journal-title":"J Thorac Dis"},{"issue":"1","key":"9490_CR18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.lungcan.2008.04.001","volume":"63","author":"J Stebbing","year":"2009","unstructured":"Stebbing J, Powles T, McPherson K, Shamash J, Wells P, Sheaff MT, Slater S, Rudd RM, Fennell D, Steele JPC. The Efficacy and Safety of Weekly Vinorelbine in Relapsed Malignant Pleural Mesothelioma. Lung Cancer. 2009;63(1):94\u20137. https:\/\/doi.org\/10.1016\/j.lungcan.2008.04.001.","journal-title":"Lung Cancer"},{"issue":"12","key":"9490_CR19","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.0.CO;2-S","volume":"85","author":"JP van Meerbeeck","year":"1999","unstructured":"van Meerbeeck JP, Baas P, Debruyne C, Groen HJ, Manegold C, Ardizzoni A, Gridelli C, van Marck EA, Lentz M, Giaccone G. A Phase II Study of Gemcitabine in Patients with Malignant Pleural Mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer. 1999;85(12):2577\u201382 (https:\/\/doi.org\/10.1002\/(sici)1097-0142(19990615)85:12%3c2577::aid-cncr13%3e3.3.co;2-j).","journal-title":"Cancer."},{"issue":"5","key":"9490_CR20","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1586\/17476348.2015.1083426","volume":"9","author":"O Abdel-Rahman","year":"2015","unstructured":"Abdel-Rahman O, Kelany M. Systemic Therapy Options for Malignant Pleural Mesothelioma beyond First-Line Therapy: A Systematic Review. Expert Rev Respir Med. 2015;9(5):533\u201349. https:\/\/doi.org\/10.1586\/17476348.2015.1083426.","journal-title":"Expert Rev Respir Med"},{"issue":"3","key":"9490_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.lungcan.2014.03.006","volume":"84","author":"MG Zauderer","year":"2014","unstructured":"Zauderer MG, Kass SL, Woo K, Sima CS, Ginsberg MS, Krug LM. Vinorelbine and Gemcitabine as Second- or Third-Line Therapy for Malignant Pleural Mesothelioma. Lung Cancer. 2014;84(3):271\u20134. https:\/\/doi.org\/10.1016\/j.lungcan.2014.03.006.","journal-title":"Lung Cancer"},{"issue":"3","key":"9490_CR22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.lungcan.2015.06.018","volume":"89","author":"WA Buikhuisen","year":"2015","unstructured":"Buikhuisen WA, Hiddinga BI, Baas P, van Meerbeeck JP. Second Line Therapy in Malignant Pleural Mesothelioma: A Systematic Review. Lung Cancer. 2015;89(3):223\u201331. https:\/\/doi.org\/10.1016\/j.lungcan.2015.06.018.","journal-title":"Lung Cancer"},{"issue":"11","key":"9490_CR23","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jtho.2018.08.007","volume":"13","author":"Y Metaxas","year":"2018","unstructured":"Metaxas Y, Rivalland G, Mauti LA, Klingbiel D, Kao S, Schmid S, Nowak AK, Gautschi O, Bartnick T, Hughes BG, Bouchaab H, Rothschild SI, Pavlakis N, Wolleb S, Petrausch U, O\u2019Byrne K, Froesch P, L\u00f6ffler-Baumann M, Pratsch-Peter S, Russell P, Mingrone W, Savic S, Thapa B, Fr\u00fch M, Pless M, von Moos R, John T. Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma. J Thorac Oncol. 2018;13(11):1784\u201391. https:\/\/doi.org\/10.1016\/j.jtho.2018.08.007.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"9490_CR24","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","volume":"20","author":"A Scherpereel","year":"2019","unstructured":"Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, D\u00f4 P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Ligeza-Poisson C, Planchard D, Amour E, Morin F, Moro-Sibilot D, Zalcman G, French Cooperative Thoracic Intergroup. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019;20(2):239\u201353. https:\/\/doi.org\/10.1016\/S1470-2045(18)30765-4.","journal-title":"Lancet Oncol."},{"issue":"6","key":"9490_CR25","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/annonc\/mdi187","volume":"16","author":"C Manegold","year":"2005","unstructured":"Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, Nackaerts K, Lianes P, Vogelzang NJ. Second-Line (Post-Study) Chemotherapy Received by Patients Treated in the Phase III Trial of Pemetrexed plus Cisplatin versus Cisplatin Alone in Malignant Pleural Mesothelioma. Ann Oncol. 2005;16(6):923\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdi187.","journal-title":"Ann Oncol"},{"issue":"2","key":"9490_CR26","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.lungcan.2007.08.031","volume":"60","author":"ARA Razak","year":"2008","unstructured":"Razak ARA, Chatten KJ, Hughes AN. Retreatment with Pemetrexed-Based Chemotherapy in Malignant Pleural Mesothelioma (MPM): A Second Line Treatment Option. Lung Cancer. 2008;60(2):294\u20137. https:\/\/doi.org\/10.1016\/j.lungcan.2007.08.031.","journal-title":"Lung Cancer"},{"issue":"5","key":"9490_CR27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10147-010-0064-7","volume":"15","author":"H Hayashi","year":"2010","unstructured":"Hayashi H, Okamoto I, Ichikawa Y, Miyazaki M, Yoshioka H, Kunimasa K, Nakagawa K. Retreatment of Recurrent Malignant Pleural Mesothelioma with Cisplatin and Pemetrexed. Int J Clin Oncol. 2010;15(5):497\u20139. https:\/\/doi.org\/10.1007\/s10147-010-0064-7.","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"9490_CR28","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pneumo.2010.07.013","volume":"66","author":"J Margery","year":"2010","unstructured":"Margery J, Rivi\u00e8re F, Planchard D, Le Floch H, Ferrand F-R, Mairovitz A, Besse B, Vaylet F, Ruffi\u00e9 P. Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005\u20132006). Rev Pneumol Clin. 2010;66(4):255\u20139. https:\/\/doi.org\/10.1016\/j.pneumo.2010.07.013.","journal-title":"Rev Pneumol Clin"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09490-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-09490-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09490-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T13:07:33Z","timestamp":1650546453000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-09490-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9490"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-09490-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,20]]},"assertion":[{"value":"9 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This is a retrospective noninterventional study and all the data were collected as a part of routine clinical practice for diagnosis and treatment according to national regulations. The study protocol was approved by the Institutional Review Board of Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch. Ethical board approval \u2013 number KB\/430\u201306\/21. Administrative permissions were obtained from the directors of oncology departments and information centre to access the raw data from the hospital medical records.The Institutional Review Board of Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch has waived the need to obtain the informed consent owing to the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"432"}}